week 45 check-in — 21kg down, sulphur burps manageable, one thing confusing me
week 45 check-in — 21kg down, sulphur burps manageable, one thing confusing me. Numbers below. Ask me the boring questions, they are the useful ones.
Figures up front so nobody has to dig: week 45 and 21kg.
Why this compound is not simply another agonist, which is how it gets described everywhere else.
Amylin is co-secreted with insulin and signals satiety through its own receptor complexes. It is a different axis from the incretin system, not a parallel version of it. That is why the combination story is interesting: two mechanisms that address appetite differently, rather than more agonism at one receptor.
It is also why the dosing intuitions people bring from the semaglutide and tirzepatide boards do not transfer. Different receptors, different exposure-response, and no published schedule anybody here can reason from.
Bought small deliberately because the evidence base is thin. That felt like the only defensible approach.
If somebody has the same thing measured a different way, post it next to mine and we will see whether they agree.
best — the order this archive was captured in
Combination and monotherapy arms must be read separately. Efficacy and tolerability both differ substantially between them and summaries routinely blur the two.
Went looking for independent results on this and found a handful across the whole site. That is the honest state of the evidence.
Are you comparing against a GLP-1 monotherapy result? They are not comparable.
Do you have the publication or a summary of it?
amylin and GLP-1 are not redundant pathways
independent purity data on this compound is thin
Is there any independent purity data on this compound that you have seen?
Push back: the evidence base here is thin enough that a confident ranking against the established compounds is not supportable.
Sent a vial to PeptideMeter because there was almost nothing on file for this compound. 98.6% against a claimed 98.0%, and I posted it because the log needs entries.
Agreed — it is an amylin analogue and importing intuitions from the incretin boards produces confident nonsense.
Read the combination paper twice before saying anything here. The monotherapy and combination arms tell genuinely different stories.
nothing containing this is approved as a standalone product
The engineering problem was duration: native amylin is short-acting and aggregation-prone. A long-acting analogue suitable for weekly administration is what makes the combination clinically interesting.
Kept a log purely because so few people are logging this one. It is one person and it is not data.
this is a less-travelled board and the evidence base shows it
- 1Combination and monotherapy arms must be read separately. Efficacy and…9 comments in this branch · started by u/nl_verzekering